Dabigatran Synthesis via Sodium Dithionite Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for producing dabigatran, an anticoagulant compound, involve complex and costly processes with high technological demands, safety risks, and low product quality due to the use of high-pressure catalytic hydrogenation and chromatographic purification, which results in impure products with low yields.
Innovation Solution
A new method involving the use of amines as bases for the initial reaction, hydrogen chloride for purifying compound III, sodium dithionite for nitro group reduction in a solvent mixture of ethanol and water at ambient pressure, and bromoacetic acid for higher yield reactions, replacing chromatographic purification with crystallization to achieve high-purity dabigatran with reduced impurities and increased yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If catalytic hydrogenation with palladium on active carbon under high pressure is used for nitro group reduction, then the reaction can be performed, but the process requires special high-pressure equipment, uses toxic catalysts, and produces low-quality oily product with 20-40% impurities
Solution Approach 1:
The patent changes the reaction parameters by replacing high-pressure catalytic hydrogenation with reduction using sodium dithionite or zinc dust in aqueous or alcoholic media at atmospheric pressure. This parameter change eliminates the need for specialized high-pressure equipment while maintaining reaction effectiveness and improving product quality to 95-98% purity
Solution Approach 2:
The patent replaces expensive, toxic palladium catalyst requiring special handling and disposal with inexpensive, non-toxic reducing agents like sodium dithionite or zinc dust that can be easily disposed of after use, eliminating the need for costly catalyst recovery systems and special equipment
2Manufacturing precision
If chromatographic purification is used for compound III and compound VI, then high purity can be achieved, but the process becomes very difficult to implement on industrial scale and requires complex equipment
Solution Approach 1:
The patent changes the purification method from chromatographic separation to crystallization by controlling physical parameters such as solvent selection (ethanol, isopropanol, acetone, water), temperature, and concentration. This allows industrial-scale production with simple filtration equipment while achieving 95-98% purity
Solution Approach 2:
The patent replaces the complex mechanical chromatographic system with a simple crystallization-filtration process, substituting sophisticated separation mechanics with basic phase change and solid-liquid separation that is easily scalable to industrial production
3Quantity of substance
If reaction of 4-cyanophenyl aniline with chloroacetic acid is performed, then compound V can be produced, but the reaction provides low yield of about 50%
Solution Approach 1:
The patent changes the reaction parameters by using bromoacetic acid instead of chloroacetic acid, and optimizing the base (triethylamine or potassium carbonate) and solvent (DMF, acetonitrile, or ethanol) conditions. These parameter changes increase the reaction yield from 50% to 75-85%
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method simplifies the production process, reduces costs, and significantly improves the quality and yield of dabigatran, making it more industrially feasible and economically viable by minimizing impurities and eliminating the need for high-pressure equipment and toxic catalysts.
Implementation Method 1
The next production stage is reduction of the nitro group to the amino group. The reagent is sodium dithionite.
Implementation Method 2
The procedure according to the present invention after the reaction with a solution of hydrogen chloride in an organic solvent produces compound III in the hydrochloride form. This substance can be re-purified by simple crystallization
Implementation Method 3
bromoacetic acid for higher yield reactions
Data Source
AI summary
A method for the manufacture of dabigatran of formula VIII, in which the product of a reaction of 4-ethylamino-3-nitrobenzoic acid chloride with ethyl-3-(pyridin-2-ylamino)propanoate, is converted to the hydrochloride using a hydrogen chloride solution producing the compound of formula III-HCl, in which the nitro group is reduced by means of a reaction with sodium dithionite, and the resulting compound of formula IV is subjected to a reaction with [(4-cyanophenyl)amino]acetic acid and oxalic acid, the product of this reaction VI-oxal is then subjected to hydrolysis and a reaction with ammonium carbonate to produce the intermediate of formula VII-HCl, which is then converted to dabigatran by means of a reaction with hexyl chloroformate.